Genmab A/S Competitors

Genmab A/S (OTCMKTS:GNMSF) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Genmab A/S and Zoetis' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Genmab A/S and Zoetis' top-line revenue, earnings per share (EPS) and valuation.

Zoetis has higher revenue and earnings than Genmab A/S.

Volatility and Risk

Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Genmab A/S shares are held by institutional investors. Comparatively, 92.5% of Zoetis shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Genmab A/S and Zoetis, as provided by MarketBeat.com.

Zoetis has a consensus target price of $180.6667, suggesting a potential upside of 4.63%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Genmab A/S.

Summary

Zoetis beats Genmab A/S on 8 of the 13 factors compared between the two stocks.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Bayer Aktiengesellschaft and Genmab A/S's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Bayer Aktiengesellschaft and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Bayer Aktiengesellschaft has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Bayer Aktiengesellschaft has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bayer Aktiengesellschaft and Genmab A/S, as reported by MarketBeat.com.

Summary

Genmab A/S beats Bayer Aktiengesellschaft on 7 of the 11 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Vertex Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Genmab A/S, as reported by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus price target of $293.4737, suggesting a potential upside of 34.68%. Given Vertex Pharmaceuticals' higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Genmab A/S.

Summary

Vertex Pharmaceuticals beats Genmab A/S on 8 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Regeneron Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Genmab A/S, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus price target of $656.3810, suggesting a potential upside of 26.96%. Given Regeneron Pharmaceuticals' higher possible upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Genmab A/S.

Summary

Regeneron Pharmaceuticals beats Genmab A/S on 7 of the 13 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (OTCMKTS:GNMSF) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 0.0% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Takeda Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Takeda Pharmaceutical and Genmab A/S, as reported by MarketBeat.com.

Valuation and Earnings

This table compares Takeda Pharmaceutical and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Summary

Genmab A/S beats Takeda Pharmaceutical on 6 of the 11 factors compared between the two stocks.

Genmab A/S (OTCMKTS:GNMSF) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

0.0% of Genmab A/S shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and Alexion Pharmaceuticals, as reported by MarketBeat.

Alexion Pharmaceuticals has a consensus target price of $159.3158, suggesting a potential downside of 8.41%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Genmab A/S.

Earnings & Valuation

This table compares Genmab A/S and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Genmab A/S.

Volatility and Risk

Genmab A/S has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Genmab A/S on 8 of the 13 factors compared between the two stocks.